Argent Biopharma ( (AU:RGT) ) just unveiled an update.
Argent BioPharma has announced a strategic manufacturing partnership with ECCPharm Limited, a leading EU-GMP-certified pharmaceutical manufacturer. This collaboration will see ECCPharm take over the manufacturing and batch release of Argent’s cannabinoid therapies, CannEpil® and CogniCann®, for early patient access programs in key EU countries. The move will transition manufacturing operations to ECCPharm’s facility in North Macedonia, aiming to enhance production efficiency and reduce operational costs for Argent. This partnership allows Argent to focus on clinical development and regulatory expansion, while ECCPharm strengthens its position in the global market for cannabinoid-based pharmaceuticals.
More about Argent Biopharma
Argent BioPharma Limited is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system disorders and immune-related conditions. The company leverages cutting-edge technologies, including the Neuro-Immune Modulatory System, to target complex diseases with a robust pipeline featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®.
YTD Price Performance: -52.50%
Average Trading Volume: 135,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.61M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.